{"transactions":[{"id":703720,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2026-07-24T13:11:48.000Z","date":"2026-07-22","kind":"sale","planned":false,"acquired":false,"shares":16085,"price":50.07,"value":805375.95,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $50.05 to $50.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."}],"balance_after":16086,"derivative":{"underlying":"Ordinary Shares","underlying_shares":48255},"source":{"system":"sec-edgar","filing":"0001193125-26-315240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526315240/ownership.xml","form_type":"4"}},{"id":703719,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2026-07-24T13:11:48.000Z","date":"2026-07-22","kind":"sale","planned":false,"acquired":false,"shares":1367,"price":50.07,"value":68445.69,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $50.05 to $50.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."}],"balance_after":1369,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4101},"source":{"system":"sec-edgar","filing":"0001193125-26-315240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526315240/ownership.xml","form_type":"4"}},{"id":724960,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2026-06-29T18:17:18.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":251488,"price":35.26,"value":8867466.88,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."}],"balance_after":854583,"source":{"system":"sec-edgar","filing":"0001193125-26-288078","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526288078/ownership.xml","form_type":"4"}},{"id":724959,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2026-06-29T18:17:18.000Z","date":"2026-06-25","kind":"sale","planned":false,"acquired":false,"shares":33372,"price":35.12,"value":1172024.64,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.39. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."}],"balance_after":1106071,"source":{"system":"sec-edgar","filing":"0001193125-26-288078","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526288078/ownership.xml","form_type":"4"}},{"id":793063,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Series D Preferred Stock","published_at":"2026-05-05T12:37:36.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":377948,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":377948},"source":{"system":"sec-edgar","filing":"0001193125-26-205201","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526205201/ownership.xml","form_type":"4"}},{"id":793062,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Series C-2 Preferred Stock","published_at":"2026-05-05T12:37:36.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":225843,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":225843},"source":{"system":"sec-edgar","filing":"0001193125-26-205201","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526205201/ownership.xml","form_type":"4"}},{"id":793061,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Series C-1 Preferred Stock","published_at":"2026-05-05T12:37:36.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":872868,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":872868},"source":{"system":"sec-edgar","filing":"0001193125-26-205201","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526205201/ownership.xml","form_type":"4"}},{"id":793060,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Series B Preferred Stock","published_at":"2026-05-05T12:37:36.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":80291,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":80291},"source":{"system":"sec-edgar","filing":"0001193125-26-205201","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526205201/ownership.xml","form_type":"4"}},{"id":793059,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Series A Preferred Stock","published_at":"2026-05-05T12:37:36.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":727585,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":727585},"source":{"system":"sec-edgar","filing":"0001193125-26-205201","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526205201/ownership.xml","form_type":"4"}},{"id":793058,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2026-05-05T12:37:36.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":377948,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":2284535,"source":{"system":"sec-edgar","filing":"0001193125-26-205201","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526205201/ownership.xml","form_type":"4"}},{"id":793057,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2026-05-05T12:37:36.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":225843,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":1906587,"source":{"system":"sec-edgar","filing":"0001193125-26-205201","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526205201/ownership.xml","form_type":"4"}},{"id":793056,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2026-05-05T12:37:36.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":872868,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":1680744,"source":{"system":"sec-edgar","filing":"0001193125-26-205201","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526205201/ownership.xml","form_type":"4"}},{"id":793055,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2026-05-05T12:37:36.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":80291,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":807876,"source":{"system":"sec-edgar","filing":"0001193125-26-205201","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526205201/ownership.xml","form_type":"4"}},{"id":793054,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2026-05-05T12:37:36.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":727585,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":727585,"source":{"system":"sec-edgar","filing":"0001193125-26-205201","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526205201/ownership.xml","form_type":"4"}},{"id":807765,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2026-04-16T18:17:23.000Z","date":"2026-04-14","kind":"sale","planned":false,"acquired":false,"shares":16085,"price":55.07,"value":885800.95,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $55.00 to $55.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."}],"balance_after":32171,"derivative":{"underlying":"Ordinary Shares","underlying_shares":48255},"source":{"system":"sec-edgar","filing":"0001193125-26-158649","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526158649/ownership.xml","form_type":"4"}},{"id":807764,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2026-04-16T18:17:23.000Z","date":"2026-04-14","kind":"sale","planned":false,"acquired":false,"shares":1367,"price":55.07,"value":75280.69,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $55.00 to $55.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."}],"balance_after":2736,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4101},"source":{"system":"sec-edgar","filing":"0001193125-26-158649","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526158649/ownership.xml","form_type":"4"}},{"id":936551,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2026-01-20T14:22:14.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":230,"price":85.04,"value":19559.2,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $85.02 to $85.06. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."}],"balance_after":48256,"derivative":{"underlying":"Ordinary Shares","underlying_shares":690},"source":{"system":"sec-edgar","filing":"0001193125-26-016062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526016062/ownership.xml","form_type":"4"}},{"id":936550,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2026-01-20T14:22:14.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":6498,"price":84.22,"value":547261.56,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $84.00 to $84.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."}],"balance_after":48486,"derivative":{"underlying":"Ordinary Shares","underlying_shares":19494},"source":{"system":"sec-edgar","filing":"0001193125-26-016062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526016062/ownership.xml","form_type":"4"}},{"id":936549,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2026-01-20T14:22:14.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":3880,"price":83.35,"value":323398.0,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $83.00 to $83.84. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."}],"balance_after":54984,"derivative":{"underlying":"Ordinary Shares","underlying_shares":11640},"source":{"system":"sec-edgar","filing":"0001193125-26-016062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526016062/ownership.xml","form_type":"4"}},{"id":936548,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2026-01-20T14:22:14.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":5477,"price":82.1,"value":449661.7,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $82.00 to $82.37. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."}],"balance_after":58864,"derivative":{"underlying":"Ordinary Shares","underlying_shares":16431},"source":{"system":"sec-edgar","filing":"0001193125-26-016062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526016062/ownership.xml","form_type":"4"}},{"id":936547,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2026-01-20T14:22:14.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":20,"price":85.04,"value":1700.8,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $85.02 to $85.06. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."}],"balance_after":4103,"derivative":{"underlying":"Ordinary Shares","underlying_shares":60},"source":{"system":"sec-edgar","filing":"0001193125-26-016062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526016062/ownership.xml","form_type":"4"}},{"id":936546,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2026-01-20T14:22:14.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":552,"price":84.22,"value":46489.44,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $84.00 to $84.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."}],"balance_after":4123,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1656},"source":{"system":"sec-edgar","filing":"0001193125-26-016062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526016062/ownership.xml","form_type":"4"}},{"id":936545,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2026-01-20T14:22:14.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":330,"price":83.35,"value":27505.5,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $83.00 to $83.84. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."}],"balance_after":4675,"derivative":{"underlying":"Ordinary Shares","underlying_shares":990},"source":{"system":"sec-edgar","filing":"0001193125-26-016062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526016062/ownership.xml","form_type":"4"}},{"id":936544,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2026-01-20T14:22:14.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":465,"price":82.1,"value":38176.5,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $82.00 to $82.37. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer."}],"balance_after":5005,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1395},"source":{"system":"sec-edgar","filing":"0001193125-26-016062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312526016062/ownership.xml","form_type":"4"}},{"id":975329,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2025-12-10T19:07:23.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":15535,"price":61.45,"value":954625.75,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $61.32 to $61.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":46605},"source":{"system":"sec-edgar","filing":"0001193125-25-313977","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525313977/ownership.xml","form_type":"4"}},{"id":975328,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2025-12-10T19:07:23.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":16635,"price":61.05,"value":1015566.75,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $60.32 to $61.31. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":15535,"derivative":{"underlying":"Ordinary Shares","underlying_shares":49905},"source":{"system":"sec-edgar","filing":"0001193125-25-313977","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525313977/ownership.xml","form_type":"4"}},{"id":975327,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2025-12-10T19:07:23.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":5589,"price":94.61,"value":528775.29,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $94.28 to $94.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":32170,"derivative":{"underlying":"Ordinary Shares","underlying_shares":16767},"source":{"system":"sec-edgar","filing":"0001193125-25-313977","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525313977/ownership.xml","form_type":"4"}},{"id":975326,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2025-12-10T19:07:23.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":2159,"price":94,"value":202946.0,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $93.27 to $94.26. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":37759,"derivative":{"underlying":"Ordinary Shares","underlying_shares":6477},"source":{"system":"sec-edgar","filing":"0001193125-25-313977","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525313977/ownership.xml","form_type":"4"}},{"id":975325,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2025-12-10T19:07:23.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":8337,"price":92.52,"value":771339.24,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $92.29 to $92.93. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":39918,"derivative":{"underlying":"Ordinary Shares","underlying_shares":25011},"source":{"system":"sec-edgar","filing":"0001193125-25-313977","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525313977/ownership.xml","form_type":"4"}},{"id":975324,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2025-12-10T19:07:23.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":1320,"price":61.45,"value":81114.0,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $61.32 to $61.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":1,"derivative":{"underlying":"Ordinary Shares","underlying_shares":3960},"source":{"system":"sec-edgar","filing":"0001193125-25-313977","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525313977/ownership.xml","form_type":"4"}},{"id":975323,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2025-12-10T19:07:23.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":1414,"price":61.05,"value":86324.7,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $60.32 to $61.31. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":1321,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4242},"source":{"system":"sec-edgar","filing":"0001193125-25-313977","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525313977/ownership.xml","form_type":"4"}},{"id":975322,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2025-12-10T19:07:23.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":475,"price":94.61,"value":44939.75,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $94.28 to $94.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":2735,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1425},"source":{"system":"sec-edgar","filing":"0001193125-25-313977","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525313977/ownership.xml","form_type":"4"}},{"id":975321,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2025-12-10T19:07:23.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":183,"price":94,"value":17202.0,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $93.27 to $94.26. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":3210,"derivative":{"underlying":"Ordinary Shares","underlying_shares":549},"source":{"system":"sec-edgar","filing":"0001193125-25-313977","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525313977/ownership.xml","form_type":"4"}},{"id":975320,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2025-12-10T19:07:23.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":709,"price":92.52,"value":65596.68,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $92.29 to $92.93. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":3393,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2127},"source":{"system":"sec-edgar","filing":"0001193125-25-313977","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525313977/ownership.xml","form_type":"4"}},{"id":998435,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-11-17T18:51:07.000Z","date":"2025-11-13","kind":"other","planned":false,"acquired":false,"shares":2230450,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-284362","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525284362/ownership.xml","form_type":"4"}},{"id":998434,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-11-17T18:51:07.000Z","date":"2025-11-13","kind":"other","planned":false,"acquired":false,"shares":3010,"ownership":{"direct":false,"nature":"F-Prime Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-284362","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525284362/ownership.xml","form_type":"4"}},{"id":1003172,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-11-12T15:48:53.000Z","date":"2025-11-10","kind":"gift","planned":false,"acquired":false,"shares":860722,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned."},"balance_after":2230450,"source":{"system":"sec-edgar","filing":"0001193125-25-276577","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525276577/ownership.xml","form_type":"4"}},{"id":1007543,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-11-05T14:57:25.000Z","date":"2025-11-03","kind":"other","planned":false,"acquired":true,"shares":2617340,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":3091172,"source":{"system":"sec-edgar","filing":"0001193125-25-266005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525266005/ownership.xml","form_type":"4"}},{"id":1007542,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-11-05T14:57:25.000Z","date":"2025-11-03","kind":"other","planned":false,"acquired":false,"shares":2356081,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Impresa Fund IV LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-266005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525266005/ownership.xml","form_type":"4"}},{"id":1007541,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-11-05T14:57:25.000Z","date":"2025-11-03","kind":"sale","planned":false,"acquired":false,"shares":193,"price":61.2281,"value":11817.0233,"ownership":{"direct":false,"nature":"Impresa Fund IV LLC"},"balance_after":2356081,"source":{"system":"sec-edgar","filing":"0001193125-25-266005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525266005/ownership.xml","form_type":"4"}},{"id":1007540,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-11-05T14:57:25.000Z","date":"2025-11-03","kind":"other","planned":false,"acquired":true,"shares":2356274,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Impresa Fund IV LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":2356274,"source":{"system":"sec-edgar","filing":"0001193125-25-266005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525266005/ownership.xml","form_type":"4"}},{"id":1007539,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-11-05T14:57:25.000Z","date":"2025-11-03","kind":"other","planned":false,"acquired":true,"shares":2115,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"F-Prime Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":3010,"source":{"system":"sec-edgar","filing":"0001193125-25-266005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525266005/ownership.xml","form_type":"4"}},{"id":1007538,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-11-05T14:57:25.000Z","date":"2025-11-03","kind":"other","planned":false,"acquired":false,"shares":47843,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VIII LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-266005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525266005/ownership.xml","form_type":"4"}},{"id":1007537,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-11-05T14:57:25.000Z","date":"2025-11-03","kind":"other","planned":false,"acquired":true,"shares":47843,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VIII LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":47843,"source":{"system":"sec-edgar","filing":"0001193125-25-266005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525266005/ownership.xml","form_type":"4"}},{"id":1007536,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-11-05T14:57:25.000Z","date":"2025-11-03","kind":"other","planned":false,"acquired":false,"shares":3189540,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VIII LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-266005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525266005/ownership.xml","form_type":"4"}},{"id":1012306,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-10-29T17:13:52.000Z","date":"2025-10-27","kind":"sale","planned":false,"acquired":false,"shares":459,"price":26.68,"value":12246.12,"ownership":{"direct":false,"nature":"FMR Capital, Inc."},"balance_after":14,"source":{"system":"sec-edgar","filing":"0001193125-25-255853","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525255853/ownership.xml","form_type":"4"}},{"id":1021879,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-10-08T19:37:41.000Z","date":"2025-10-06","kind":"gift","planned":false,"acquired":false,"shares":1232434,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned."},"balance_after":841231,"source":{"system":"sec-edgar","filing":"0001193125-25-234461","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525234461/ownership.xml","form_type":"4"}},{"id":1021878,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-10-08T19:35:08.000Z","date":"2025-10-06","kind":"gift","planned":false,"acquired":false,"shares":633715,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned."},"balance_after":473832,"source":{"system":"sec-edgar","filing":"0001193125-25-234456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000119312525234456/ownership.xml","form_type":"4"}},{"id":1042321,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-09-12T20:09:01.000Z","date":"2025-09-02","kind":"other","planned":false,"acquired":true,"shares":1107547,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This amendment is being filed to correct the number of shares previously reported as being indirectly acquired by persons and entities whose shares are subject to reporting by the undersigned."}],"balance_after":1107547,"source":{"system":"sec-edgar","filing":"0000950170-25-114526","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025114526/ownership.xml","form_type":"4/A","original_submission_date":"2025-09-04"}},{"id":1048884,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-09-04T18:58:55.000Z","date":"2025-09-02","kind":"other","planned":false,"acquired":true,"shares":1134258,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":1134258,"source":{"system":"sec-edgar","filing":"0000950170-25-113013","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025113013/ownership.xml","form_type":"4"}},{"id":1048883,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-09-04T18:58:55.000Z","date":"2025-09-02","kind":"sale","planned":false,"acquired":false,"shares":268,"price":36,"value":9648.0,"ownership":{"direct":false,"nature":"Impresa Fund IV LLC"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-113013","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025113013/ownership.xml","form_type":"4"}},{"id":1048882,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-09-04T18:58:55.000Z","date":"2025-09-02","kind":"other","planned":false,"acquired":false,"shares":997044,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Impresa Fund IV LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":268,"source":{"system":"sec-edgar","filing":"0000950170-25-113013","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025113013/ownership.xml","form_type":"4"}},{"id":1048881,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-09-04T18:58:55.000Z","date":"2025-09-02","kind":"other","planned":false,"acquired":true,"shares":997312,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Impresa Fund IV LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":997312,"source":{"system":"sec-edgar","filing":"0000950170-25-113013","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025113013/ownership.xml","form_type":"4"}},{"id":1048880,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Shares","published_at":"2025-09-04T18:58:55.000Z","date":"2025-09-02","kind":"other","planned":false,"acquired":true,"shares":895,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"F-Prime Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":895,"source":{"system":"sec-edgar","filing":"0000950170-25-113013","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025113013/ownership.xml","form_type":"4"}},{"id":1048879,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-09-04T18:58:55.000Z","date":"2025-09-02","kind":"other","planned":false,"acquired":false,"shares":20250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VIII LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-113013","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025113013/ownership.xml","form_type":"4"}},{"id":1048878,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-09-04T18:58:55.000Z","date":"2025-09-02","kind":"other","planned":false,"acquired":true,"shares":20250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VIII LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":20250,"source":{"system":"sec-edgar","filing":"0000950170-25-113013","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025113013/ownership.xml","form_type":"4"}},{"id":1048877,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-09-04T18:58:55.000Z","date":"2025-09-02","kind":"other","planned":false,"acquired":false,"shares":1350000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VIII LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":3189540,"source":{"system":"sec-edgar","filing":"0000950170-25-113013","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025113013/ownership.xml","form_type":"4"}},{"id":1077966,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-08-01T13:36:26.000Z","date":"2025-07-30","kind":"sale","planned":false,"acquired":false,"shares":48374,"price":20.5,"value":991667.0,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned."},"balance_after":2073665,"source":{"system":"sec-edgar","filing":"0000950170-25-101143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025101143/ownership.xml","form_type":"4"}},{"id":1077965,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2025-08-01T13:34:05.000Z","date":"2025-07-30","kind":"sale","planned":false,"acquired":false,"shares":26310,"price":17.87,"value":470159.7,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":1515558,"derivative":{"underlying":"Ordinary Shares","underlying_shares":78930},"source":{"system":"sec-edgar","filing":"0000950170-25-101141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025101141/ownership.xml","form_type":"4"}},{"id":1277837,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2025-02-10T13:36:12.000Z","date":"2025-02-06","kind":"sale","planned":false,"acquired":false,"shares":41,"price":30.54,"value":1252.14,"ownership":{"direct":false,"nature":"FIMM, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":123},"source":{"system":"sec-edgar","filing":"0000950170-25-016705","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025016705/ownership.xml","form_type":"4"}},{"id":1283029,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Series A Preferred Stock","published_at":"2025-02-05T16:39:25.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":3120934,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VIII LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3120934},"source":{"system":"sec-edgar","filing":"0000950170-25-014244","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025014244/ownership.xml","form_type":"4"}},{"id":1283028,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Series Seed Preferred Stock","published_at":"2025-02-05T16:39:25.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":1418606,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VIII LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1418606},"source":{"system":"sec-edgar","filing":"0000950170-25-014244","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025014244/ownership.xml","form_type":"4"}},{"id":1283027,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-02-05T16:39:25.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":true,"shares":3120934,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VIII LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":4539540,"source":{"system":"sec-edgar","filing":"0000950170-25-014244","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025014244/ownership.xml","form_type":"4"}},{"id":1283026,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-02-05T16:39:25.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":true,"shares":1418606,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VIII LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":1418606,"source":{"system":"sec-edgar","filing":"0000950170-25-014244","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025014244/ownership.xml","form_type":"4"}},{"id":1306119,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-01-10T18:32:59.000Z","date":"2025-01-08","kind":"sale","planned":false,"acquired":false,"shares":1000,"price":7.26,"value":7260.0,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"balance_after":4541511,"source":{"system":"sec-edgar","filing":"0000950170-25-004052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025004052/ownership.xml","form_type":"4"}},{"id":1306118,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-01-10T18:32:59.000Z","date":"2025-01-08","kind":"sale","planned":false,"acquired":false,"shares":164912,"price":6.71,"value":1106559.52,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.20 to $6.98. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":4542511,"source":{"system":"sec-edgar","filing":"0000950170-25-004052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025004052/ownership.xml","form_type":"4"}},{"id":1306117,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-01-10T18:32:59.000Z","date":"2025-01-08","kind":"sale","planned":false,"acquired":false,"shares":25000,"price":6.5,"value":162500.0,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.50 to $6.55. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":4707423,"source":{"system":"sec-edgar","filing":"0000950170-25-004052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025004052/ownership.xml","form_type":"4"}},{"id":1306116,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2025-01-10T18:32:59.000Z","date":"2025-01-08","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":6.11,"value":611000.0,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.05 to $6.24. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":4732423,"source":{"system":"sec-edgar","filing":"0000950170-25-004052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017025004052/ownership.xml","form_type":"4"}},{"id":1404258,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series C Preferred Stock","published_at":"2024-09-18T15:54:10.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":392085,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VII LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":392085},"source":{"system":"sec-edgar","filing":"0000950170-24-107660","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017024107660/ownership.xml","form_type":"4"}},{"id":1404257,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B Preferred Stock","published_at":"2024-09-18T15:54:10.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":712430,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VII LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":712430},"source":{"system":"sec-edgar","filing":"0000950170-24-107660","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017024107660/ownership.xml","form_type":"4"}},{"id":1404256,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series Seed Preferred Stock","published_at":"2024-09-18T15:54:10.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":10818,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VII LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10818},"source":{"system":"sec-edgar","filing":"0000950170-24-107660","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017024107660/ownership.xml","form_type":"4"}},{"id":1404255,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2024-09-18T15:54:10.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":392085,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VII LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":1115333,"source":{"system":"sec-edgar","filing":"0000950170-24-107660","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017024107660/ownership.xml","form_type":"4"}},{"id":1404254,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2024-09-18T15:54:10.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":712430,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VII LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":723248,"source":{"system":"sec-edgar","filing":"0000950170-24-107660","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017024107660/ownership.xml","form_type":"4"}},{"id":1404253,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2024-09-18T15:54:10.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":10818,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VII LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":10818,"source":{"system":"sec-edgar","filing":"0000950170-24-107660","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017024107660/ownership.xml","form_type":"4"}},{"id":1573830,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2024-03-18T12:52:33.000Z","date":"2024-03-14","kind":"sale","planned":false,"acquired":false,"shares":21997,"price":35,"value":769895.0,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":1541868,"derivative":{"underlying":"Ordinary Shares","underlying_shares":65991},"source":{"system":"sec-edgar","filing":"0000950170-24-032542","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000095017024032542/ownership.xml","form_type":"4"}},{"id":1642097,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2024-02-15T19:34:14.000Z","date":"2024-02-14","kind":"sale","planned":false,"acquired":false,"shares":45677,"price":31.34,"value":1431517.18,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $31.25 to $31.58. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":1235511,"source":{"system":"sec-edgar","filing":"0001209191-24-003394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919124003394/doc4.xml","form_type":"4"}},{"id":1642096,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2024-02-15T19:34:14.000Z","date":"2024-02-14","kind":"sale","planned":false,"acquired":false,"shares":854323,"price":30.51,"value":26065394.73,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $30.25 to $31.25. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":1281188,"source":{"system":"sec-edgar","filing":"0001209191-24-003394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919124003394/doc4.xml","form_type":"4"}},{"id":1642095,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2024-02-15T19:34:14.000Z","date":"2024-02-13","kind":"sale","planned":false,"acquired":false,"shares":1155,"price":30.93,"value":35724.15,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned"},"balance_after":2771913,"source":{"system":"sec-edgar","filing":"0001209191-24-003394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919124003394/doc4.xml","form_type":"4"}},{"id":1642094,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2024-02-15T19:34:14.000Z","date":"2024-02-13","kind":"sale","planned":false,"acquired":false,"shares":410,"price":30.28,"value":12414.8,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned"},"balance_after":2773068,"source":{"system":"sec-edgar","filing":"0001209191-24-003394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919124003394/doc4.xml","form_type":"4"}},{"id":1642093,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2024-02-15T16:11:48.000Z","date":"2024-02-13","kind":"sale","planned":false,"acquired":false,"shares":525,"price":47.24,"value":24801.0,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":1563865,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1575},"source":{"system":"sec-edgar","filing":"0001209191-24-003392","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919124003392/doc4.xml","form_type":"4"}},{"id":1699870,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2023-12-27T15:56:07.000Z","date":"2023-12-22","kind":"other","planned":false,"acquired":false,"shares":29549,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."}],"balance_after":2773478,"source":{"system":"sec-edgar","filing":"0001209191-23-059756","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123059756/doc4.xml","form_type":"4"}},{"id":1699869,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2023-12-27T15:49:09.000Z","date":"2023-12-22","kind":"other","planned":false,"acquired":false,"shares":25410,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Shares held by persons and entities whose shares are subject to reporting by the undersigned"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":1564390,"derivative":{"underlying":"Ordinary Shares","underlying_shares":76230},"source":{"system":"sec-edgar","filing":"0001209191-23-059755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123059755/doc4.xml","form_type":"4"}},{"id":1719559,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2023-12-07T16:04:44.000Z","date":"2023-12-05","kind":"sale","planned":false,"acquired":false,"shares":16086,"price":62.46,"value":1004731.56,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $62.35 to $62.63. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":32169,"derivative":{"underlying":"Ordinary Shares","underlying_shares":48258},"source":{"system":"sec-edgar","filing":"0001209191-23-057698","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123057698/doc4.xml","form_type":"4"}},{"id":1719558,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2023-12-07T16:04:44.000Z","date":"2023-12-05","kind":"sale","planned":false,"acquired":false,"shares":1368,"price":62.46,"value":85445.28,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $62.35 to $62.63. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice."}],"balance_after":2733,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4104},"source":{"system":"sec-edgar","filing":"0001209191-23-057698","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123057698/doc4.xml","form_type":"4"}},{"id":1728155,"issuer":{"id":51131,"kind":"organization","name":"Fidelity Private Credit Fund","symbol":"NONE"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Class D Common Shares of Beneficial Interest","published_at":"2023-11-29T19:57:03.000Z","date":"2023-11-29","kind":"purchase","planned":false,"acquired":true,"shares":391.495,"price":25.54,"value":9998.7823,"ownership":{"direct":false,"nature":"FMR Capital Inc."},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 1, 2023, the Reporting Person's subscription to purchase Class S and Class D Common Shares of the Issuer was accepted. On November 29, 2023, the number of shares being purchased by the Reporting Person was fixed when the purchase price per share was determined by the Issuer."}],"balance_after":391.495,"source":{"system":"sec-edgar","filing":"0001209191-23-056886","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123056886/doc4.xml","form_type":"4"}},{"id":1728154,"issuer":{"id":51131,"kind":"organization","name":"Fidelity Private Credit Fund","symbol":"NONE"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Class S Common Shares of Beneficial Interest","published_at":"2023-11-29T19:57:03.000Z","date":"2023-11-29","kind":"purchase","planned":false,"acquired":true,"shares":391.495,"price":25.54,"value":9998.7823,"ownership":{"direct":false,"nature":"FMR Capital Inc."},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 1, 2023, the Reporting Person's subscription to purchase Class S and Class D Common Shares of the Issuer was accepted. On November 29, 2023, the number of shares being purchased by the Reporting Person was fixed when the purchase price per share was determined by the Issuer."}],"balance_after":391.495,"source":{"system":"sec-edgar","filing":"0001209191-23-056886","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123056886/doc4.xml","form_type":"4"}},{"id":1756640,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2023-10-23T19:55:27.000Z","date":"2023-10-18","kind":"sale","planned":false,"acquired":false,"shares":16086,"price":65.64,"value":1055885.04,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.  Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP (\"Fund VI\") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP (\"FPCPLSA\") converted 16,407 ordinary shares to 5,469 ADSs.  Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS  as shown in Column 9."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $65.52 to $65.70. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.  Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP (\"Fund VI\") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP (\"FPCPLSA\") converted 16,407 ordinary shares to 5,469 ADSs.  Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS  as shown in Column 9."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.  Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP (\"Fund VI\") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP (\"FPCPLSA\") converted 16,407 ordinary shares to 5,469 ADSs.  Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS  as shown in Column 9."}],"balance_after":48255,"derivative":{"underlying":"Ordinary Shares","underlying_shares":48258},"source":{"system":"sec-edgar","filing":"0001209191-23-053321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123053321/doc4.xml","form_type":"4"}},{"id":1756639,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"American Depositary Shares","published_at":"2023-10-23T19:55:27.000Z","date":"2023-10-18","kind":"sale","planned":false,"acquired":false,"shares":1368,"price":65.64,"value":89795.52,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Advisors Fund VI LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.  Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP (\"Fund VI\") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP (\"FPCPLSA\") converted 16,407 ordinary shares to 5,469 ADSs.  Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS  as shown in Column 9."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $65.52 to $65.70. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.  Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP (\"Fund VI\") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP (\"FPCPLSA\") converted 16,407 ordinary shares to 5,469 ADSs.  Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS  as shown in Column 9."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.  Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP (\"Fund VI\") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP (\"FPCPLSA\") converted 16,407 ordinary shares to 5,469 ADSs.  Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS  as shown in Column 9."}],"balance_after":4101,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4104},"source":{"system":"sec-edgar","filing":"0001209191-23-053321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123053321/doc4.xml","form_type":"4"}},{"id":1775866,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-2 Preferred Stock","published_at":"2023-09-21T12:30:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":88289,"ownership":{"direct":false,"nature":"FBRI LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":88289},"source":{"system":"sec-edgar","filing":"0001209191-23-050240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123050240/doc4.xml","form_type":"4"}},{"id":1775865,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B Preferred Stock","published_at":"2023-09-21T12:30:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":84965,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VII LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":84965},"source":{"system":"sec-edgar","filing":"0001209191-23-050240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123050240/doc4.xml","form_type":"4"}},{"id":1775864,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-2 Preferred Stock","published_at":"2023-09-21T12:30:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":3475646,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VII LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3475646},"source":{"system":"sec-edgar","filing":"0001209191-23-050240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123050240/doc4.xml","form_type":"4"}},{"id":1775863,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-2 Preferred Stock","published_at":"2023-09-21T12:30:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":63724,"ownership":{"direct":false,"nature":"F-Prime Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":63724},"source":{"system":"sec-edgar","filing":"0001209191-23-050240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123050240/doc4.xml","form_type":"4"}},{"id":1775862,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2023-09-21T12:30:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":88289,"ownership":{"direct":false,"nature":"FBRI LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":88289,"source":{"system":"sec-edgar","filing":"0001209191-23-050240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123050240/doc4.xml","form_type":"4"}},{"id":1775861,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2023-09-21T12:30:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":63724,"ownership":{"direct":false,"nature":"F-Prime Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":63724,"source":{"system":"sec-edgar","filing":"0001209191-23-050240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123050240/doc4.xml","form_type":"4"}},{"id":1775860,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2023-09-21T12:30:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":84965,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VII LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":5472340,"source":{"system":"sec-edgar","filing":"0001209191-23-050240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123050240/doc4.xml","form_type":"4"}},{"id":1775859,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2023-09-21T12:30:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":3475646,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Life Sciences Fund VII LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":5387375,"source":{"system":"sec-edgar","filing":"0001209191-23-050240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123050240/doc4.xml","form_type":"4"}},{"id":1822509,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Series B-2 Preferred Stock","published_at":"2023-07-27T12:42:15.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":4939,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Advisors Fund V LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4939},"source":{"system":"sec-edgar","filing":"0001209191-23-043464","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123043464/doc4.xml","form_type":"4"}},{"id":1822508,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Series B-2 Preferred Stock","published_at":"2023-07-27T12:42:15.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":296396,"ownership":{"direct":false,"nature":"Impresa Fund III Limited Partnership"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":296396},"source":{"system":"sec-edgar","filing":"0001209191-23-043464","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123043464/doc4.xml","form_type":"4"}},{"id":1822507,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Series B-1 Preferred Stock","published_at":"2023-07-27T12:42:15.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":483684,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":483684},"source":{"system":"sec-edgar","filing":"0001209191-23-043464","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123043464/doc4.xml","form_type":"4"}},{"id":1822506,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":28868,"kind":"organization","name":"FMR LLC","position":1,"cik":"0000315066","reported_name":"FMR LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remark 1"}}],"security":"Series B-2 Preferred Stock","published_at":"2023-07-27T12:42:15.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":150809,"ownership":{"direct":false,"nature":"F-Prime Capital Partners Healthcare Fund V LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":150809},"source":{"system":"sec-edgar","filing":"0001209191-23-043464","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/315066/000120919123043464/doc4.xml","form_type":"4"}}],"next_cursor":"2023-07-27T12:42:15.000000Z,1822506"}